< 回列表
陸英明
- President & Chief Medical Officer (Group); Chief Executive Officer (U.S.A.) HanchorBio (漢康生技)
Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
| 角色 | 講師 |
| 日期時間 | 05/02 10:00 - 11:00 |
| 地點 | 701D |
Beyond CD47 Blockade: Redefining the CD47-SIPRα Field for Next-Generation Innate Immunotherapy
| 角色 | 講師 |
| 日期時間 | 05/02 15:05 - 15:55 |
| 地點 | 701D |
學歷 / 訓練
MBA, Harvard Business School
PhD., Neuroscience, University of California, San Francisco
M.S., Cell Development & Physiology, University of California, Berkeley
B.S., Biochemistry, University of California, Berkeley
專業與研究經歷
Broad of Directors Member, HanchorBio (漢康生技)
Global Senior Clinical Advisor, HanchorBio/Hanchor Biopharma (漢康生物)
Chairman of Scientific Advisory Board, Zhongmou Therapeutics (中眸醫療科技)
Co-Founder, CEO, and Board of Directors Member, HuidaGene Therapeutics (輝大基因)
獲獎與榮譽
2025
TIME100 Health Honoree (2025)
2008
Bayer® Star Award
2004
American Society of Hematology Excellence Award